Science

ESMO Global Consortium Study on the availability and accessibility of cancer medicines

Nathan I. Cherny/szmc.org

Jan 16, 2025, 23:54

ESMO Global Consortium Study on the availability and accessibility of cancer medicines

The European Society for Medical Oncology (ESMO) shared a recent article by N.I. Cherny et al. on X:

“The results of the ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines are now available in Annals of Oncology with the latest 2023 update.”

“ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update“

Authors: N.I. Cherny, D. Trapani, M. Galotti, M. Saar, G. Bricalli, F. Roitberg, B. Gyawali, G. Curigliano, J.-Y. Blay, K. Meier, N.J. Latino4 and E.G.E. de Vries

ESMO Global Consortium Study

More posts featuring The European Society for Medical Oncology.

cancer cancer medicines D. Trapani E.G.E. de Vries ESMO Global Consortium Study European Society for Medical Oncology F. Roitberg G. Bricalli M. Galotti M. Saar N.I. Cherny OncoDaily Oncology

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer